Hepatic Artery Infusion Pump for NPC Liver Metastases

Inclusion Criteria: * Histologically confirmed nasopharyngeal carcinoma with histologically confirmed or image diagnosed metastatic to the liver * Standard treatment of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) is performed as desired * Performance status - ECOG 0-2 * Absolute neutrophil count at least 1,200/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST no greater than 2.5 times ULN * Alkaline phosphatase no greater than 2.5 times ULN * No pre-existing chronic hepatic disease (chronic active hepatitis or cirrhosis) * Creatinine no greater than ULN * Creatinine clearance greater than 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Adequate oral nutrition (at least 1,500 calories/day) * Able to withstand major operative procedure * No dehydration * No severe anorexia * No frequent nausea or vomiting * No prior or concurrent malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of any organ * No prior or concurrent malignancy associated with more than 10% probability of death from malignant disease within 5 years of diagnosis * No concurrent immunotherapy * No concurrent colony-stimulating factors during the first course of study therapy * No more than 1 prior adjuvant systemic fluorouracil (5-FU) regimen with or without levamisole, leucovorin calcium, or irinotecan * No prior hepatic artery infusion therapy with 5-FU or floxuridine * No prior systemic chemotherapy for metastatic disease * No prior or concurrent sorivudine or brivudine